Inhibitors of advanced glycation end products (AGEs): Potential utility for the treatment of cardiovascular disease

Cardiovascular Therapeutics

Volumn 26, Issue 1, 2008, Pages 50-58

  Yamagishi, Sho Ichi ^a   Nakamura, Kazuo ^a   Matsui, Takanori ^a   Ueda, So ^a   Noda, Yoshihiro ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGEs; CVD; Oxidative stress; RAGE

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOGUANIDINE; AST 120; ATORVASTATIN; BROMIDE; GUANIDINE DERIVATIVE; LOSARTAN; METFORMIN; N PHENACYLTHIAZOLIUM BROMIDE; PYRIDOXAMINE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE CONTROL; DRUG EFFECT; DRUG INHIBITION; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VASCULITIS;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 47049105636     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2007.00038.x     Document Type: Review

References (77)

1. Alderson NL, Chachich MN, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW (2003) The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63 : 2123 2133.
2. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334 : 574 579.
3. Beisswenger P, Ruggiero-Lopez D (2003) Metformin inhibition of glycation processes. Diabetic Metab 29 : 6S95 103.
4. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, et al 2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24 : 32 40.
5. Brown BE, Mahroof FM, Cook NL, Van Reyk DM, Davies MJ (2006) Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. Diabetologia 49 : 775 783.
6. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414 : 813 820.
7. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232 : 1629 1632.
8. Bucala, Cerami A (1992) Advanced glycosylation: Chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23 : 1 34.
9. Bucala, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91 : 9441 9445.
10. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, et al 2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Cir Res 92 : 785 792.
11. Chang KC, Tseng CD, Wu MS, Liang JT, Tsai MS, Cho YL, Tseng YZ (2006) Aminoguanidine prevents arterial stiffening in a new rat model type 2 diabetes. Eur J Clin Invest 36 : 528 535.
12. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, et al 2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. Lancet 364 : 685 696.
13. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaboration Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: A randomized placebo-controlled trial. Lancet 361 : 2005 2016.
14. Demiot C, Fromy B, Saumet JL, Sigaudo-Roussel D (2006) Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice. Cardiovasc Res 69 : 245 252.
15. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW (1991) Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266 : 11654 11660.
16. Endo N, Nishiyama K, Okabe M, Matsumoto M, Kanouchi H, Oka T (2007) Vitamine B6 suppresses apoptosis of NM-1 bovine endothelial cells induced by homocysteine and copper. Biochim Biophys Acta 1770 : 571 577.
17. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, et al 2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51 : 3274 3282.
18. Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME (2004) The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl 92 : S105 107.
19. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, et al 2004) Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53 : 1813 1823.
20. Giannoukakis N (2005) Pyridoxamine. Curr Opin Investig Drugs 6 : 410 418.
21. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products. Sparking the development of diabetic vascular injury. Circulation 114 : 597 605.
22. Grandhee SK, Monnier VM (1991) Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 266 : 11649 11653.
23. Huijberts MS, Wolffenbuttel BH, Boudier HA, Crijns FR, Kruseman AC, Poitevin P, Levy BI (1993) Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 92 : 1407 1411.
24. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, O'brien R, Cooper ME, Chin-Dusting JP, Sviridov D (2007) Advanced glycation of apolipoprotein A-1 impairs its anti-atherogenic properties. Diabetologia 50 : 1170 1179.
25. Jinnouchi Y, Yamagishi S, Takeuchi M, Ishida S, Jinnouchi Y, Jinnouchi J, Imaizumi T (2006) Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 6 : 191 193.
26. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, DeGroof RC, Lakatta EG (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104 : 1464 1470.
27. Kikuchi S, Shinpo K, Takeuchi M, Yamagishi S, Makita Z, Sasaki N, Tashiro K (2003) Glycation-a sweet temper for neuronal death. Brain Res Brain Res Rev 41 : 306 323.
28. Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K (2005) Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 20 : 1647 1658.
29. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC (2005) The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11 : 191 195.
30. Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue H (2007) Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma. J Int Med Res 35 : 482 489.
31. Miyata T, Ishikawa S, Asahi K, Inagi R, Suzuki D, Horie K, Tatsumi K, Kurokawa K (1999) 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: Role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 445 : 202 206.
32. Miyata T, Van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K (2002) Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanism. J Am Soc Nephrol 13 : 2478 2487.
33. Mizutani K, Ikeda K, Tsuda K, Yamori Y (2002) Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J Hypertens 20 : 1607 1614.
34. Monacelli F, Poggi A, Storace D, Durante A, Traverso N, Viviani GL, Odetti P (2006) Effects of valsartan therapy on protein glycoxidation. Metabolism 55 : 1619 1624.
35. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T (1997) Progression of nephropathy in spontaneous diabetic rat is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46 : 895 899.
36. Nakamura S, Li H, Adijiang A, Pischetsrieder M, Niwa T (2007) Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant 22 : 2165 2174.
37. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 : 2643 2653.
38. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S (1997) The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 62 : S23 S28.
39. Norton GR, Candy G, Woodiwiss AJ (1996) Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93 : 1905 1912.
40. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW (2000) Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 275 : 21177 21184.
41. Ouslimani N, Mahrouf M, Peynet J, Bonnefont-Rousselot D, Cosson C, Legrand A, Beaudeux JL (2007) Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism 56 : 308 313.
42. Panagiotopoulos S, O'Brien RC, Bucala R, Cooper ME, Jerums G (1998) Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 136 : 125 131.
43. Picard S, Parthasarathy S, Fruebis J, Witztum JL (1992) Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 89 : 6876 6880.
44. Price DL, Rhett PM, Thorpe SR, Baynes JW (2001) Chelating activity of advance glycation end-product inhibitors. J Biol Chem 276 : 48967 48972.
45. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL (2000) Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 301 : 65 77.
46. Regan TJ, Jyothirmayi GN, Laharm C, Jain A (2001) Left ventricular diastolic dysfunction in diabetic or hypertensive subjects: Role of collagen alterations. Adv Exp Med Biol 498 : 127 132.
47. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N (1999) Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 58 : 1765 1773.
48. Saisho Y, Komiya N, Hirose H (2006) Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 74 : 201 203.
49. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M (2006) Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen 21 : 197 208.
50. Schmidt AM, Stern D (2000) Atherosclerosis and diabetes: The RAGE connection. Curr Atheroscler Rep 2 : 430 436.
51. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N (2006) A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 47 : 565 577.
52. Sebekova K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, Heidland A (1999) Advanced glycation end-product levels in subtotally nephrectomized rats: Beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab 25 : 380 383.
53. Sebekova K, Gazdikova K, Syrova D, Blazicek P, Schinzel R, Heidland A, Spustova V, Dzurik R (2003) Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 17 : 265 270.
54. Shimoi K, Okitsu A, Green MH, Lowe JE, Ohta T, Kaji K, Terato H, Ide H, Kinae N (2001) Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells. Mutat Res 480-481 : 371 378.
55. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T (2006) Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 3 : 73 77.
56. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342 : 381 389.
57. Thornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419 : 31 40.
58. Thornalley PJ, Yurek-George A, Argirov OK (2000) Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 60 : 55 65.
59. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T (1999) Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42 : 579 588.
60. Ueda S, Yamagishi S, Takeuchi M, Kohno K, Shibata R, Matsumoto Y, Kaneyuki U, Fujimura T, Hayashida A, Okuda S (2006) Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med 12 : 180 184.
61. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 : 854 865.
62. Usta MF, Kendiric M, Gur S, Foxwell NA, Bivalacqua TJ, Cellek S, Hellstrom WL (2006) Breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats; Preventive versus curative treatment. J Sex Med 3 : 242 250.
63. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, et al 1996) An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382 : 275 278.
64. Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70 : 138 51.
65. Voziyan PA, Hudson BG (2005) Pyridoxamine as a multifunctional pharmaceutical: Targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 62 : 1671 1681.
66. Voziyan PA, Metz TO, Baynes JW, Hudson BG (2002) A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277 : 3397 3403.
67. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, et al 1998) Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 95 : 4630 4634.
68. Writing Team For The Diabetes Control And Complications Trial/Epidemiology Of Diabetes Interventions And Complications Research Group (2003) Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290 : 2159 2167.
69. Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11 : 2279 2299.
70. Yamagishi S, Nakamura K, Takeuchi M, Imaizumi T (2004) Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention. Int J Clin Pharmacol Res 24 : 129 134.
71. Yamagishi S, Matsui T, Nakamura K (2006) Atorvastatin and diabetic vascular complications. Curr Pharm Des 12 : 1549 1554.
72. Yamagishi S, Ueda S, Okuda S (2007) Food-derived advanced glycation end products (AGEs): A novel therapeutic target for various disorders. Curr Pharm Des 13 : 2832 2836.
73. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, et al 2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108 : 261 268.
74. Yokosuka K, Park JS, Jimbo K, Yoshida K, Sato K, Tsuru M, Takeuchi M, Yamagishi S, Nagata K (2006) Advanced glycation end-products downregulating intervertebral disc cell production of proteoglycans in vitro. J Neurosurg Spine 5 : 324 329.
75. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M (2006) Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 49 : 3094 3099.
76. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Makino T, Shimizu T, Sata M (2007) Atorvastatin inhibits advanced glycation end products (AGEs)-induced C-reactive protein expression in hepatoma cells by suppressing reactive oxygen species generation. Vasc Dis Prevention 4 : 213 216.
77. Zieman SJ, Melenovsky V, Clattenburg L, Corretti MC, Capriotti A, Gerstenblith G, Kass DA (2007) Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 25 : 577 583.